Desperate lung cancer patients get access to experimental drug
NCT ID NCT04741789
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This program offers capmatinib, an oral drug, to people with advanced non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is a managed access (compassionate use) program, not a formal study. The goal is to provide potential benefit when no satisfactory alternative exists.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capmatinib (also known as INC280), a tablet taken by mouth
What this could lead to
If successful, this program could provide a treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is not a clinical trial testing effectiveness; it is a compassionate-use program. Results may vary, and risks are not fully studied in this setting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.